Will new autoimmune drugs address cost concerns? December 27, 2016 By Erin Bastick PharmD Find out what’s in the drug pipeline for autoimmune disease. Top 2017 challenges healthcare executives face December 08, 2016 By Karen Appold Results from Managed Healthcare Executive’s annual State of the Industry Survey reveal which issues will hit managed healthcare hardest in 2017. Are payers optimistic about biosimilars’ savings? December 07, 2016 By Erin Bastick As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications. Four innovative models rein in pharma costs December 05, 2016 By Mari Edlin Plans and PBMs are finding new ways to rein in pharmacy costs. Hodgkin lymphoma: First hematologic cancer cured with immunotherapy? December 05, 2016 By Bryant Furlow Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more. Integrating pharmacy benefit, medical benefit cuts costs November 29, 2016 By Tracey Walker Here’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs. Aggressive price growth pushes healthcare spending up November 25, 2016 By Tracey Walker Rise in use of outpatient care and professional services contributed to quicker growth in spending for the privately insured over previous years. Four ways Medicare Part D has affected costs for diabetic patients November 22, 2016 By Tracey Walker Understand Medicare Part D’s design and its coverage gap to offer the most affordable prescription drug options for patients. Three data-driven practices that boost adherence November 17, 2016 By Neil Smiley Here’s a three-pronged approach to improve adherence program efficiency that leverages predictive data analytics, hospital on-site pharmacies and post discharge follow-up evaluation to achieve real, measurable results. Five things physicians don’t know about biosimilars November 14, 2016 By Tracey Walker Awareness of biosimilars is high, but there are some gaps to be filled, according to a Biosimilars Forum study.